Wed, 04th Feb 2015 13:37
** British drugmaker's U.S.-listed shares up 2.5 pctat $45.35 premarket
** Company reports better-than-expected Q4 earnings,helped by cost cuts
** GSK reports lower-than-expected Q4 revenue, hurt by weaksales of lung drug Advair
** Up to Tuesday's close, U.S.-listed stock had fallen about13 pct in past 12 months
June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert ...
June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert ...
May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Frid...
May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on ...
CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer resp...
Glaxosmithkline (GSK)